159 related articles for article (PubMed ID: 1531075)
21. Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.
Bøgesø KP; Arnt J; Frederiksen K; Hansen HO; Hyttel J; Pedersen H
J Med Chem; 1995 Oct; 38(22):4380-92. PubMed ID: 7473566
[TBL] [Abstract][Full Text] [Related]
22. Existence of dopamine D1 receptor on the sympathetic nerve endings in the guinea-pig vas deferens.
Furukawa T; Morishita H
Eur J Pharmacol; 1997 Jun; 328(2-3):229-34. PubMed ID: 9218705
[TBL] [Abstract][Full Text] [Related]
23. [3H]SCH 23390 binding to human putamen D-1 dopamine receptors: stereochemical and structure-affinity relationships among 1-phenyl-1H-3-benzazepine derivatives as a guide to D-1 receptor topography.
O'Boyle KM; Waddington JL
J Neurochem; 1987 Apr; 48(4):1039-42. PubMed ID: 2950206
[TBL] [Abstract][Full Text] [Related]
24. Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434.
Abrahams BS; Rutherford JD; Mallet PE; Beninger RJ
Eur J Pharmacol; 1998 Feb; 343(2-3):111-8. PubMed ID: 9570457
[TBL] [Abstract][Full Text] [Related]
25. Modulation of in vivo dopamine release by D2 but not D1 receptor agonists and antagonists.
Boyar WC; Altar CA
J Neurochem; 1987 Mar; 48(3):824-31. PubMed ID: 2949060
[TBL] [Abstract][Full Text] [Related]
26. Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels.
Kuzhikandathil EV; Oxford GS
Mol Pharmacol; 2002 Jul; 62(1):119-26. PubMed ID: 12065762
[TBL] [Abstract][Full Text] [Related]
27. Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines.
Pfeiffer FR; Wilson JW; Weinstock J; Kuo GY; Chambers PA; Holden KG; Hahn RA; Wardell JR; Tobia AJ; Setler PE; Sarau HM
J Med Chem; 1982 Apr; 25(4):352-8. PubMed ID: 7069713
[TBL] [Abstract][Full Text] [Related]
28. Radiosynthesis of a selective dopamine D-1 receptor antagonist: R(+)-7-chloro-8-hydroxy-3-[11C]methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3 -benzazepine ([11C]SCH 23390).
Ravert HT; Wilson AA; Dannals RF; Wong DF; Wagner HN
Int J Rad Appl Instrum A; 1987; 38(4):305-6. PubMed ID: 3040632
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D(1) receptor activities.
Zhang J; Chen X; Yu L; Zhen X; Zhang A
Bioorg Med Chem; 2008 Nov; 16(21):9425-31. PubMed ID: 18835172
[TBL] [Abstract][Full Text] [Related]
30. Behavioral effects of D1 and D2 dopamine receptor antagonists in squirrel monkeys.
Bergman J; Madras BK; Spealman RD
J Pharmacol Exp Ther; 1991 Sep; 258(3):910-7. PubMed ID: 1890625
[TBL] [Abstract][Full Text] [Related]
31. Structural determinants of selective affinity for brain D-1 dopamine receptors within a series of 1-phenyl-1H-3-benzazepine analogues of SK&F 38393 and SCH 23390.
O'Boyle KM; Waddington JL
Eur J Pharmacol; 1985 Sep; 115(2-3):291-5. PubMed ID: 2866103
[TBL] [Abstract][Full Text] [Related]
32. Dopaminergic inhibition of catecholamine secretion from chromaffin cells: evidence that inhibition is mediated by D4 and D5 dopamine receptors.
Dahmer MK; Senogles SE
J Neurochem; 1996 Jan; 66(1):222-32. PubMed ID: 8522958
[TBL] [Abstract][Full Text] [Related]
33. Dopamine D1 receptor mediation of the discriminative stimulus properties of SKF 38393.
Cunningham KA; Callahan PM; Appel JB
Eur J Pharmacol; 1985 Dec; 119(1-2):121-5. PubMed ID: 2935415
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
Macdonald GJ; Branch CL; Hadley MS; Johnson CN; Nash DJ; Smith AB; Stemp G; Thewlis KM; Vong AK; Austin NE; Jeffrey P; Winborn KY; Boyfield I; Hagan JJ; Middlemiss DN; Reavill C; Riley GJ; Watson JM; Wood M; Parker SG; Ashby CR
J Med Chem; 2003 Nov; 46(23):4952-64. PubMed ID: 14584946
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.
Giri R; Namballa HK; Sarker A; Alberts I; Harding WW
Bioorg Med Chem Lett; 2020 Aug; 30(16):127305. PubMed ID: 32631525
[TBL] [Abstract][Full Text] [Related]
36. Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzaz epi ne-7, 8-diol. 6-Position modifications.
Ross ST; Franz RG; Gallagher G; Brenner M; Wilson JW; DeMarinis RM; Hieble JP; Sarau HM
J Med Chem; 1987 Jan; 30(1):35-40. PubMed ID: 3806602
[TBL] [Abstract][Full Text] [Related]
37. Structural analogs of SCH 23390 as discriminators of dopamine receptor subtypes: behavioral interactions between D-1 and D-2 agonists and antagonists.
O'Boyle KM; Molloy AG; Mashurano M; Waddington JL
Psychopharmacol Bull; 1986; 22(3):599-604. PubMed ID: 2879303
[No Abstract] [Full Text] [Related]
38. Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy.
Andersen PH; Jansen JA
Eur J Pharmacol; 1990 Jun; 188(6):335-47. PubMed ID: 1973652
[TBL] [Abstract][Full Text] [Related]
39. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors.
Andringa G; Drukarch B; Leysen JE; Cools AR; Stoof JC
Eur J Pharmacol; 1999 Jan; 364(1):33-41. PubMed ID: 9920182
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, pharmacological evaluations, and molecular docking studies on a new 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework: Rigidification of D
Giri R; Alberts I; Harding WW
Chem Biol Drug Des; 2020 Aug; 96(2):825-835. PubMed ID: 32279445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
